Open an account

Benitec Biopharma

BNTC · NASDAQ

$9.04+$0.68 (+8.13%)TodayMarket closed ·
Prev close $8.36

About BNTC

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Employees
19
Headquarters
Hayward, California
Listed
Jul 11, 2012
Sector
Health Care
Industry
Biotechnology
Website
benitec.com

BNTC key statistics

Market cap
315.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
198.73K
Volume
347.61K
Open price
$8.35
High today
$9.29
Low today
$8.32
52 Week high
$16.76
52 Week low
$8.00

Benitec Biopharma (BNTC) at a glance

Benitec Biopharma (BNTC) last traded at $9.04, with a market cap of 315.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.32 and $9.29. The current price is 8.7% above the day's low and 2.7% below its high.

Volume so far is 347.61K shares, above the average of 198.73K shares a day.

Over the past year Benitec Biopharma has ranged from $8.00 to $16.76, and now sits 12% of the way up that range.

Benitec Biopharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY26 it reported -$0.26 per share against an estimate of -$0.2754.

The average analyst price target is $24.82, 174.6% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $24.82
Low
$17.17
Now
$9.04
High
$33.60

BNTC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 27.6% on average.

  1. Q1 FY25: reported -$0.48 per share against an estimate of -$0.561
  2. Q2 FY25: reported -$0.33 per share against an estimate of -$0.7851
  3. Q3 FY25: reported -$0.24 per share against an estimate of -$0.3548
  4. Q4 FY25: reported -$0.42 per share against an estimate of -$0.2958
  5. Q1 FY26: reported -$0.22 per share against an estimate of -$0.3757
  6. Q2 FY26: reported -$0.26 per share against an estimate of -$0.2278
  7. Q3 FY26: reported -$0.24 per share against an estimate of -$0.2791
  8. Q4 FY26: reported -$0.26 per share against an estimate of -$0.2754

BNTC news

  • Press releaseBusiness Wire

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

  • Press releaseBusiness Wire

    Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

  • Press releaseGlobe Newswire

    Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

  • Press releaseGlobe Newswire

    Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

  • Press releaseGlobe Newswire

    Benitec Biopharma Announces Updated Investor Webcast Information

  • Press releaseGlobe Newswire

    Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Similar companies

Companies in the same industry as Benitec Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.